Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

Healthcare Cannabis
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Medipharm Labs Corp > Organigram Invests in Germany
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(71)
•••
Comment by QContinuum1on Jun 26, 2024 9:35am
65 Views
Post# 36106722

RE:RE:RE:Organigram Invests in Germany

RE:RE:RE:Organigram Invests in Germany
QContinuum1 wrote:
mdjbrown wrote: QC1, especially when considering the following statement in Labs last German update In addition to STADA sales

Summary of MediPharm Labs Business Operations in Germany

Beacon Medical GMBH  

  • Beacon Medical is a wholly owned subsidiary of MediPharm Labs. Located in Potsdam, the business holds a suite of German GMP medical cannabis licenses to import, wholesale and distribute GMP cannabis products. 
  • Beacon Medical is a medical product brand with distribution via German partners Adrex Pharma, Cansativa and Medical Pharma Resource.
  • Thus far in 2024, MediPharm has increased the German product approvals under the Beacon Medical brand from 5 to 14. 


Not sure how our partners stack up against Sanity Group.  Hoping that they do given the BAT investment in Sanity (and OGI) and their undoubted strategy team doing their DD.

If Stada is #2 in oils, and our claim to fame is oils and the med market is increasing by 30-50%, something has to give/break.  That of course doesn't consider the other partners either as you've mentioned.

Much to talk about tomorrow.


Turns out that Vayamed (who LABS apparently had(s) an agreement with is just arms length of Sanity.  How incestuous. 

MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

 

Published
  • New strategic partnership through the delivery of GMP extract to Germany for Vayamed, the medical cannabis business unit of Sanity Group
  • Vayamed is a well-established operating medical cannabis company in Germany, where the medical cannabis market is expected to be worth €7.7 billion by 2028 according to Forbes
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities